We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Adrenal Function in Patients With Newly Diagnosed Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00364624
Recruitment Status : Completed
First Posted : August 15, 2006
Last Update Posted : January 16, 2009
Information provided by:

Study Description
Brief Summary:
Patients with newly diagnosed lung cancer may have hypofunction of the adrenal cortex either from tumour metastasis or other mechanisms. Since lung cancer patient may have to undergo stressful investigation and treatments, undetected hypofunction of the adrenal cortex may be hazardous. Knowledge of the size of the problem may help determine whether routine check is warranted.

Condition or disease
Lung Cancer Adrenal Insufficiency

Study Design

Study Type : Observational
Actual Enrollment : 133 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Adrenal Cortical Function in Patients With Newly Diagnosed Lung Cancer
Study Start Date : August 2006
Primary Completion Date : April 2008
Study Completion Date : May 2008

Groups and Cohorts

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with newly diagnosed, histologically confirmed primary lung cancer

Inclusion Criteria:

  • Histologically proven primary lung cancer
  • Newly diagnosed
  • No specific treatment given
  • No active infection in the previous week
  • No general anesthesia in the previous week

Exclusion Criteria:

  • Known adrenal disease
  • Receiving exogenous systemic corticosteroids
  • Concomitant illness known to affect adrenal function. e.g. active TB
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00364624

China, Hong Kong SAR
Department of Medicine, Princess Margaret Hospital
Kowloon, Hong Kong SAR, China
Sponsors and Collaborators
Princess Margaret Hospital, Hong Kong
Principal Investigator: Wai C YU, MBBS Princess Margaret Hospital, Hong Kong
More Information

Responsible Party: Dr. W C Yu, Consultant Physician, Princess Margaret Hospital, Hong Kong
ClinicalTrials.gov Identifier: NCT00364624     History of Changes
Other Study ID Numbers: KW/FR/06-008
First Posted: August 15, 2006    Key Record Dates
Last Update Posted: January 16, 2009
Last Verified: January 2009

Keywords provided by Princess Margaret Hospital, Hong Kong:
lung cancer
adrenal insufficiency

Additional relevant MeSH terms:
Lung Neoplasms
Adrenal Insufficiency
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Adrenal Gland Diseases
Endocrine System Diseases
Epinephryl borate
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Vasoconstrictor Agents